Ming. quarter by our a was you, and driven for Precision Precision We had core XX% Thank in growth our Diagnostics record up year-over-year sequentially. strong business, Diagnostics XX% division.
the we of seeing one are leaders. cemented our Screening have our as We strong as services, demand Care ourselves for product, reproductive Beacon market now Expanded specifically
During divisions the other meet Pharma having with strong saw Services another we expectations quarter, our quarter.
bit However, be the Pharma Services lumpy as a we expect timing on of previously we the depending to mentioned, service contracts.
Services Pharma to and we backlog pipeline strong remain leverage as our spatial multi-omics expanded in continue our forward, biology. and capabilities Looking
was like volume volume this on sequencing able were Not next-generation we to time increase technology XXX% COVID-XX investments have the stress platform of of able capabilities. with showing lab this and the We perform our evidence power overall We are since incremental in quarter. we did only minimal tested and up real-world turnaround year-over-year. were again, feel and take lab we Fulgent platform with to technology Overall the and services time temporary operations time. minimal
by are built laboratory stated and we that founded, before engineers. designed a We
using to to and lab scale cost was be a testing hires. the to mission professional on continually able automation, high informatics create AI Our operation differentiated genomic layering without of
sequencing. highest installed sequencers, cost our and and to allowing additional to-date, the also we quarter, expand most the the us exome and additionally During recent lower capacity of throughput genome
by few them together our Coast be two to new we the two lead We the West completed consolidating and operational lab for aim the miles operations end recently buildings Bringing Historically, one. quarter. also of third We begun cost efficiency. move apart. into should have a to occupied
continues Beacon this Expanded one and offering, controls for as in the product us time. space Fulgent have to labs a turnaround Care company. the our of end-to-end driver to a be handle cost allowing that growth key few stands Screening on better out
market As We've to to turnaround we the we the capturing ramp improvement are in penetrate good space, and market and costs share job volume, done will on future. in process to improve we focused look continue meaningful OB time. infertility the lower a
standard version, which includes a around built genes, already next adoption of more clinicians today most of and larger panel more the we've are this While using panel. care, are XXX of seeing genes, we XXX a and
broader XXX look to over Our is that thought genes. to the we've few going years, genes seen clinicians coverage, what will is which XXX process approximately from last continue for approximately
most our Before be probes at and our could an be sequencing robust alignment time, too exome tools, to efficient the ready along bioinformatics with address long, which test capture capacity. with we'll proprietary sequence
of Pathology to division continues to cycle perform with improve others. standardization and Anatomic management, on our logistics among improvements Our well include managed care, continuing These of revenue a operations. systems, lot focus
turnaround Digital have addition, to quality. heavily pathology space, time, we in cost the pathology. In better is digital and been investing leading revolutionizing
of shipping plus and one the associated the to to at prepared day least glass costs slides example, our and physical storage. labs our For shipping burden clients had
and immediately. share scan, can electronically we Now digitize
have to the clients images cases. In even the built our addition, their own sign allow to only we of digital one end-to-end or view out solutions
to Turning Fulgent Oncology.
beyond by and tumor priced Now turn our Lumera MolDX heme soft at our NGS the solid with both to approved on and $X,XXX, expanding West we respectively, attention launch profile our $X,XXX and Lumera Coast. our
placed with team continue is a a small nation a multidisciplinary have grow. Armed one-stop for of oncology reps territories in the testing. We portfolio, Fulgent across expect number near to shop and this specialty to strategic Oncology
penetrate We to will feel West community segment and that able contender cancer a the precision as beyond to diagnostics. ourselves national we Coast be establish oncology the very strongly in continue
As remain prospects the the second forward. we performance encouraged moving and see with the quarter during Ming are we by mentioned, business we pleased
Paul walk now the to Kim, our over detailed through the financials. I'll call Paul? turn CFO, to
